299 related articles for article (PubMed ID: 30036348)
1. Baricitinib (olumiant) for rheumatoid arthritis.
Med Lett Drugs Ther; 2018 Jul; 60(1551):120-121. PubMed ID: 30036348
[No Abstract] [Full Text] [Related]
2. Baricitinib: A Review in Rheumatoid Arthritis.
Al-Salama ZT; Scott LJ
Drugs; 2018 May; 78(7):761-772. PubMed ID: 29687421
[TBL] [Abstract][Full Text] [Related]
3. FDA issues concerns about optimal baricitinib doses for the treatment of moderate-to-severe rheumatoid arthritis and delays drug approval.
Rheumatology (Oxford); 2017 Aug; 56(8):e22. PubMed ID: 28854620
[No Abstract] [Full Text] [Related]
4. Efficacy and safety of baricitinib in Japanese patients with rheumatoid arthritis: Subgroup analyses of four multinational phase 3 randomized trials.
Tanaka Y; Atsumi T; Amano K; Harigai M; Ishii T; Kawaguchi O; Rooney TP; Akashi N; Takeuchi T
Mod Rheumatol; 2018 Jul; 28(4):583-591. PubMed ID: 29134891
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of baricitinib in the treatment of rheumatoid arthritis.
Richez C; Truchetet ME; Kostine M; Schaeverbeke T; Bannwarth B
Expert Opin Pharmacother; 2017 Sep; 18(13):1399-1407. PubMed ID: 28737053
[TBL] [Abstract][Full Text] [Related]
6. Drugs for rheumatoid arthritis.
Med Lett Drugs Ther; 2018 Jul; 60(1552):123-128. PubMed ID: 30044766
[No Abstract] [Full Text] [Related]
7. Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study.
Tanaka Y; Ishii T; Cai Z; Schlichting D; Rooney T; Macias W
Mod Rheumatol; 2018 Jan; 28(1):20-29. PubMed ID: 28440680
[TBL] [Abstract][Full Text] [Related]
8. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
Taylor PC; Keystone EC; van der Heijde D; Weinblatt ME; Del Carmen Morales L; Reyes Gonzaga J; Yakushin S; Ishii T; Emoto K; Beattie S; Arora V; Gaich C; Rooney T; Schlichting D; Macias WL; de Bono S; Tanaka Y
N Engl J Med; 2017 Feb; 376(7):652-662. PubMed ID: 28199814
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis.
Keystone EC; Genovese MC; Schlichting DE; de la Torre I; Beattie SD; Rooney TP; Taylor PC
J Rheumatol; 2018 Jan; 45(1):14-21. PubMed ID: 28811354
[TBL] [Abstract][Full Text] [Related]
10. An EUA for baricitinib (Olumiant) for COVID-19.
Med Lett Drugs Ther; 2020 Dec; 62(1614):202-203. PubMed ID: 33451175
[No Abstract] [Full Text] [Related]
11. Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study.
Tanaka Y; Emoto K; Cai Z; Aoki T; Schlichting D; Rooney T; Macias W
J Rheumatol; 2016 Mar; 43(3):504-11. PubMed ID: 26834213
[TBL] [Abstract][Full Text] [Related]
12. Risk of Adverse Drug Events Observed with Baricitinib 2 mg Versus Baricitinib 4 mg Once Daily for the Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Huang F; Luo ZC
BioDrugs; 2018 Oct; 32(5):415-423. PubMed ID: 30203252
[TBL] [Abstract][Full Text] [Related]
13. Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment.
Veeravalli V; Dash RP; Thomas JA; Babu RJ; Madgula LMV; Srinivas NR
Drug Saf; 2020 Aug; 43(8):711-725. PubMed ID: 32367507
[TBL] [Abstract][Full Text] [Related]
14. Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis.
Mogul A; Corsi K; McAuliffe L
Ann Pharmacother; 2019 Sep; 53(9):947-953. PubMed ID: 30907116
[No Abstract] [Full Text] [Related]
15. Two new drugs for rheumatoid arthritis.
Drug Ther Bull; 2017 Sep; 55(9):102-105. PubMed ID: 28882850
[TBL] [Abstract][Full Text] [Related]
16. Safety of Baricitinib 4 mg for the Treatment of Moderate to Severe Rheumatoid Arthritis.
Dabal TD; Haltom MB; Patel PP; Son CK; Joglekar KP; Groeschell CM; Chumpia MM; Kamal SF; Seth A; Jackson CD
South Med J; 2021 May; 114(5):288-292. PubMed ID: 33942113
[TBL] [Abstract][Full Text] [Related]
17. The safety of baricitinib in patients with rheumatoid arthritis.
Honda S; Harigai M
Expert Opin Drug Saf; 2020 May; 19(5):545-551. PubMed ID: 32174196
[No Abstract] [Full Text] [Related]
18. Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials.
Qiu C; Zhao X; She L; Shi Z; Deng Z; Tan L; Tu X; Jiang S; Tang B
Lipids Health Dis; 2019 Feb; 18(1):54. PubMed ID: 30777075
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Bae SC; Lee YH
Z Rheumatol; 2019 Aug; 78(6):559-567. PubMed ID: 30191390
[TBL] [Abstract][Full Text] [Related]
20. Upadacitinib (Rinvoq) - a new JAK inhibitor for rheumatoid arthritis.
Med Lett Drugs Ther; 2019 Nov; 61(1585):183-185. PubMed ID: 31770358
[No Abstract] [Full Text] [Related]
[Next] [New Search]
